Acquisition of Selexys Pharmaceuticals Corp.


Our attorneys represented long-time client Novartis in its exclusive option to acquire Selexys Pharmaceuticals Corp. and its lead asset, monoclonal antibody SelG1, for up to $665 million.

The Oklahoma City-based Selexys is developing drugs to treat chronic inflammatory and thrombotic diseases such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis and others.

Email Disclaimer